Ally Olotu1, Gregory Fegan1, Juliana Wambua1, George Nyangweso1, Amanda Leach1, Marc Lievens1, David C Kaslow1, Patricia Njuguna1, Kevin Marsh1, Philip Bejon1. 1. From the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Programme, Kilifi, Kenya (A.O., G.F., J.W., G.N., P.N., K.M., P.B.); Ifakara Health Institute, Bagamoyo, Tanzania (A.O.); the Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (G.F., K.M., P.B.); GlaxoSmithKline Vaccines, Wavre, Belgium (A.L., M.L.); and PATH, Seattle (D.C.K.).
Abstract
BACKGROUND: The candidate malaria vaccine RTS,S/AS01 is being evaluated in order to inform a decision regarding its inclusion in routine vaccination schedules. METHODS: We conducted 7 years of follow-up in children who had been randomly assigned, at 5 to 17 months of age, to receive three doses of either the RTS,S/AS01 vaccine or a rabies (control) vaccine. The end point was clinical malaria (temperature of ≥37.5°C and infection with Plasmodium falciparum of >2500 parasites per cubic millimeter). In an analysis that was not prespecified, the malaria exposure of each child was estimated with the use of information on the prevalence of malaria among residents within a 1-km radius of the child's home. Vaccine efficacy was defined as 1 minus the hazard ratio or the incidence-rate ratio, multiplied by 100, in the RTS,S/AS01 group versus the control group. RESULTS: Over 7 years of follow-up, we identified 1002 episodes of clinical malaria among 223 children randomly assigned to the RTS,S/AS01 group and 992 episodes among 224 children randomly assigned to the control group. The vaccine efficacy, as assessed by negative binomial regression, was 4.4% (95% confidence interval [CI], -17.0 to 21.9; P=0.66) in the intention-to-treat analysis and 7.0% (95% CI, -14.5 to 24.6; P=0.52) in the per-protocol analysis. Vaccine efficacy waned over time (P=0.006 for the interaction between vaccination and time), including negative efficacy during the fifth year among children with higher-than-average exposure to malaria parasites (intention-to-treat analysis: -43.5%; 95% CI, -100.3 to -2.8 [P=0.03]; per-protocol analysis: -56.8%; 95% CI, -118.7 to -12.3 [P=0.008]). CONCLUSIONS: A three-dose vaccination with RTS,S/AS01 was initially protective against clinical malaria, but this result was offset by rebound in later years in areas with higher-than-average exposure to malaria parasites. (Funded by the PATH Malaria Vaccine Initiative and others; ClinicalTrials.gov number, NCT00872963.).
BACKGROUND: The candidate malaria vaccine RTS,S/AS01 is being evaluated in order to inform a decision regarding its inclusion in routine vaccination schedules. METHODS: We conducted 7 years of follow-up in children who had been randomly assigned, at 5 to 17 months of age, to receive three doses of either the RTS,S/AS01 vaccine or a rabies (control) vaccine. The end point was clinical malaria (temperature of ≥37.5°C and infection with Plasmodium falciparum of >2500 parasites per cubic millimeter). In an analysis that was not prespecified, the malaria exposure of each child was estimated with the use of information on the prevalence of malaria among residents within a 1-km radius of the child's home. Vaccine efficacy was defined as 1 minus the hazard ratio or the incidence-rate ratio, multiplied by 100, in the RTS,S/AS01 group versus the control group. RESULTS: Over 7 years of follow-up, we identified 1002 episodes of clinical malaria among 223 children randomly assigned to the RTS,S/AS01 group and 992 episodes among 224 children randomly assigned to the control group. The vaccine efficacy, as assessed by negative binomial regression, was 4.4% (95% confidence interval [CI], -17.0 to 21.9; P=0.66) in the intention-to-treat analysis and 7.0% (95% CI, -14.5 to 24.6; P=0.52) in the per-protocol analysis. Vaccine efficacy waned over time (P=0.006 for the interaction between vaccination and time), including negative efficacy during the fifth year among children with higher-than-average exposure to malaria parasites (intention-to-treat analysis: -43.5%; 95% CI, -100.3 to -2.8 [P=0.03]; per-protocol analysis: -56.8%; 95% CI, -118.7 to -12.3 [P=0.008]). CONCLUSIONS: A three-dose vaccination with RTS,S/AS01 was initially protective against clinical malaria, but this result was offset by rebound in later years in areas with higher-than-average exposure to malaria parasites. (Funded by the PATH Malaria Vaccine Initiative and others; ClinicalTrials.gov number, NCT00872963.).
Authors: Joe J Campo; John J Aponte; Jeff Skinner; Rie Nakajima; Douglas M Molina; Li Liang; Jahit Sacarlal; Pedro L Alonso; Peter D Crompton; Philip L Felgner; Carlota Dobaño Journal: Mol Cell Proteomics Date: 2014-12-29 Impact factor: 5.911
Authors: Martin P Grobusch; Julian J Gabor; John J Aponte; Norbert G Schwarz; Marc Poetschke; Jenny Doernemann; Katharina Schuster; Kai B Koester; Katharina Profanter; Lea B Borchert; Florian Kurth; Peter Pongratz; Saadou Issifou; Bertrand Lell; Peter G Kremsner Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Philip Bejon; Jackie Cook; Elke Bergmann-Leitner; Ally Olotu; John Lusingu; Jedidah Mwacharo; Johan Vekemans; Patricia Njuguna; Amanda Leach; Marc Lievens; Sheetij Dutta; Lorenz von Seidlein; Barbara Savarese; Tonya Villafana; Martha M Lemnge; Joe Cohen; Kevin Marsh; Patrick H Corran; Evelina Angov; Eleanor M Riley; Chris J Drakeley Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Ally Olotu; Gregory Fegan; Juliana Wambua; George Nyangweso; Edna Ogada; Chris Drakeley; Kevin Marsh; Philip Bejon Journal: PLoS One Date: 2012-03-29 Impact factor: 3.240
Authors: Nicolas Senn; Patricia Rarau; Danielle I Stanisic; Leanne Robinson; Céline Barnadas; Doris Manong; Mary Salib; Jonah Iga; Nandao Tarongka; Serej Ley; Anna Rosanas-Urgell; John J Aponte; Peter A Zimmerman; James G Beeson; Louis Schofield; Peter Siba; Stephen J Rogerson; John C Reeder; Ivo Mueller Journal: PLoS Med Date: 2012-03-27 Impact factor: 11.069
Authors: Philip Bejon; Thomas N Williams; Christopher Nyundo; Simon I Hay; David Benz; Peter W Gething; Mark Otiende; Judy Peshu; Mahfudh Bashraheil; Bryan Greenhouse; Teun Bousema; Evasius Bauni; Kevin Marsh; David L Smith; Steffen Borrmann Journal: Elife Date: 2014-04-24 Impact factor: 8.140
Authors: Ally Olotu; Gregory Fegan; Juliana Wambua; George Nyangweso; Ken O Awuondo; Amanda Leach; Marc Lievens; Didier Leboulleux; Patricia Njuguna; Norbert Peshu; Kevin Marsh; Philip Bejon Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245
Authors: Abdisalan M Noor; Damaris K Kinyoki; Clara W Mundia; Caroline W Kabaria; Jonesmus W Mutua; Victor A Alegana; Ibrahima Socé Fall; Robert W Snow Journal: Lancet Date: 2014-02-20 Impact factor: 202.731
Authors: Isabelle Zenklusen; Said Jongo; Salim Abdulla; Kamaka Ramadhani; B Kim Lee Sim; Hayley Cardamone; Erika L Flannery; Thao Nguyen; Matthew Fishbaugher; Ryan W J Steel; Will Betz; Nelly Carmago; Sebastian Mikolajczak; Stefan H I Kappe; Stephen L Hoffman; Brandon K Sack; Claudia Daubenberger Journal: J Infect Dis Date: 2018-04-23 Impact factor: 5.226
Authors: Edrous Alamer; Victor H Carpio; Samad A Ibitokou; Michelle L Kirtley; Inaia R Phoenix; Michael M Opata; Kyle D Wilson; Yingzi Cong; Sara M Dann; Ashok K Chopra; Robin Stephens Journal: Parasitol Res Date: 2019-05-23 Impact factor: 2.289
Authors: Elizabeth T Rogawski; James A Platts-Mills; E Ross Colgate; Rashidul Haque; K Zaman; William A Petri; Beth D Kirkpatrick Journal: J Infect Dis Date: 2018-03-05 Impact factor: 5.226